Davis's Drug Guide
linvoseltamab
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
**REMS Drug**
Pronunciation:
lin-voe-sel-ta-mab
Trade Name(s)
- Lynozyfic
Ther. Class.
Pharm. Class.
T-cell engagers
monoclonal antibodies
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., and Cynthia A. Sanoski. "Linvoseltamab." Davis's Drug Guide Davis's Drug Guide, 20th ed., F.A. Davis Company, 2026. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580209/all/linvoseltamab.
Vallerand AHA, Sanoski CAC. Linvoseltamab. Davis's Drug Guide Davis's Drug Guide. F.A. Davis Company; 2026. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580209/all/linvoseltamab. Accessed October 12, 2026.
Vallerand, A. H., & Sanoski, C. A. (2026). Linvoseltamab. In Davis's Drug Guide Davis's Drug Guide (20th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580209/all/linvoseltamab
Vallerand AHA, Sanoski CAC. Linvoseltamab [Internet]. In: Davis's Drug Guide Davis's Drug Guide. F.A. Davis Company; 2026. [cited 2026 October 12]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580209/all/linvoseltamab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - linvoseltamab
ID - 3580209
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580209/all/linvoseltamab
PB - F.A. Davis Company
ET - 20
DB - Pediatrics Central
DP - Unbound Medicine
ER -
